Clinical Data Receives FDA 510(k) Clearance for Nanopia Wide Range CRP Assay.

NEWTON, Mass. -- Clinical Data, Inc. (NASDAQ: CLDA), a worldwide leader in commercializing pharmacogenomics to guide drug utilization, today announced that its Vital Diagnostics division has received clearance from the Food and Drug Administration to market a wide range C-Reactive Protein (wrCRP) assay, trademarked as the Nanopia wrCRP Assay.

The Nanopia wrCRP is an in vitro diagnostic used for the quantitative measurement of C-Reactive Protein in serum or plasma. C-reactive protein (CRP) is a blood component that increases rapidly in infections, tissue trauma, surgery, or other injury to the body. CRP elevates within 4 to 6 hours after the infection or injury occurs. Levels may increase up to 1000 times normal and peak in about 24 to 48 hours. Decreases in CRP occur very rapidly after trauma or infection resolves. The rapid rise and fall of CRP concentrations make it very useful as a nonspecific indicator of acute inflammation. Elevated CRP occurs in conditions such as bacterial and viral infections, malignancies, tuberculosis, rheumatoid arthritis, and heart attack.

Clinical Data's President and CEO, Israel M. Stein, M.D., said, "We are pleased to have received the necessary FDA 510(k) clearance to market this diagnostic test for high sensitivity C-Reactive Protein in the United States. Objective estimates of the U.S. market suggest that over 20 million CRP tests were ordered in 2005 and test use appears to be growing."

Dr. Stein continued, "In February 2005, Clinical Data announced that it had entered into a partnering relationship with Daiichi Pure Chemicals, a subsidiary of Daiichi Sankyo of Japan to bring novel technology to the world diagnostics market. Daiichi Pure Chemicals has demonstrated through its long successful history that it has a superior capability for developing unique technology and a firm commitment to serving the needs of the medical diagnostic community. We view Daiichi Pure Chemicals as a perfect partner for this and other specialized applications that are being developed for the clinical chemistry platform. The successful marketing clearance we have received from the FDA for this proprietary Daiichi assay marks the first major milestone for this partnership.

Separately, the Company also previously noted that IVD registration under European regulations will also be sought for this assay.

About Daiichi Pure Chemicals Co., Ltd.

Daiichi Pure Chemicals, Co., Ltd. headquartered in Tokyo, Japan, is a life science company having four business areas: diagnostics, research products, fine chemicals, and contract research. Diagnostics is its core business. Daiichi has developed the homogeneous HDL-C and LDL-C reagents and distributes these products worldwide through overseas partner companies. Daiichi has a focus on effective in-vitro testing for life style related diseases, cardiovascular disease, infectious disease, cancer, thrombosis, and diabetes. Daiichi seeks new business opportunities in the evolving market for diagnostics, and believes the collaboration with Clinical Data, Inc. will contribute to promising business in the future.

About Clinical Data, Inc.

Clinical Data, Inc. is a worldwide leader in providing molecular services and clinical diagnostics to improve patient care. Clinical Data's molecular services division is among the largest independent providers of pharmacogenomics and metabolomics services globally and consolidates the operations of Genaissance Pharmaceuticals, Inc., Lark Technologies, Inc. and Icoria, Inc., each acquired during 2005. The division is utilizing pharmacogenomics to develop molecular diagnostics and more efficacious therapeutics by finding genetic markers to guide drug development and utilization. These services are marketed to the pharmaceutical, biotech, clinical, academic, government and agricultural marketplaces. Clinical Data's Vital Diagnostics division consolidates the operations of Clinical Data Sales & Service, Inc., Vital Scientific NV, Vital Diagnostics Pty. Ltd., and Electa Lab s.r.l., which are each focused on the small volume clinical diagnostics market worldwide. Vital Diagnostics' instrumentation business has a market focus on the physician's office, hospital and small-to-medium sized laboratory segments. With customers in approximately 100 countries, Vital Diagnostics has also achieved a leading market share for instruments and reagents sold into moderately complex physicians' office laboratories within the United States.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This press release contains certain forward-looking information and statements that are intended to be covered by the safe harbor for forward looking statements provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)", "feel(s)", "believe(s)", "will", "may", "anticipate(s)" and similar expressions are intended to identify forward-looking statements. Such statements are subject to certain risks and uncertainties, the effects of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to, whether Clinical Data will be able to develop or acquire additional products and attract new business and strategic partners; competition from pharmaceutical, biotechnology and diagnostics companies; the strength of our intellectual property rights; the effect on the Company's operations and results of significant acquisitions or divestitures made by major competitors; the Company's ability to achieve expected synergies and operating efficiencies in all of its acquisitions, and to successfully integrate its operations; and those risks discussed and identified by Clinical Data in its public filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Clinical Data does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Readers are also urged to carefully review and consider the various disclosures in Clinical Data's SEC reports, including but not limited to its Annual Report on Form 10-KSB for the fiscal year ended March 31, 2005, and fiscal 2005 and 2006 quarterly reports on Forms 10-QSB and 10-Q.